Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34009622/

Chimeric antigen receptor T (CAR-T)-cell therapy is a promising treatment for relapsed/refractory multiple myeloma (RRMM). In our previous report, CD19- and BCMA-targeted CAR-T co-administration was associated with a high response...

How to Treat High-Risk Myeloma at Diagnosis and Relapse - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34010042/

Survival in multiple myeloma has improved greatly during the past 2 decades, but this change has primarily benefited patients who have standard-risk disease. Patients with high-risk disease remain a challenge...

When and How to Treat Relapsed Multiple Myeloma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34010043/

The treatment landscape for relapsed multiple myeloma has expanded considerably in recent years, as numerous agents with new mechanisms of action have been introduced, increasing responses even in advanced disease...

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/33980831/

doi: 10.1038/s41408-021-00478-4. 1 Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA. 2 Unité Hémopathies Lymphoïdes, CHU Henri Mondor, Créteil, France. 3 Service d'hématologie, CHRU Hôpitaux de...

tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/33971811/

doi: 10.1186/s12859-021-04167-8. 1 Department of Hematology, The Third Xiangya Hospital of Central South University, Changsha, 410000, China. 2 Department of Blood Transfusion, The Seventh Affiliated Hospital of Sun Yat-Sen University,...